Aurora Cannabis (NYSE:ACB) Stock Rating Lowered by Bank of America

Bank of America lowered shares of Aurora Cannabis (NYSE:ACB) from a buy rating to a neutral rating in a report published on Thursday, 24/7 WallStreet reports. They currently have $7.30 price target on the stock.

A number of other analysts also recently issued reports on ACB. LADENBURG THALM/SH SH started coverage on shares of Acreage in a report on Wednesday, July 17th. They issued a buy rating and a $18.00 price target on the stock. ValuEngine downgraded shares of WideOpenWest from a hold rating to a sell rating in a report on Friday, June 28th. Desjardins restated a buy rating on shares of Horizons Enhcd Inc Eqy Cl E Unt Etf in a report on Thursday, April 25th. Zacks Investment Research upgraded shares of Golub Capital BDC from a hold rating to a buy rating and set a $20.00 target price on the stock in a report on Tuesday, July 16th. Finally, Stifel Nicolaus reduced their target price on shares of MacroGenics from $36.00 to $29.00 and set a buy rating on the stock in a report on Wednesday, June 5th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of $8.72.

Shares of NYSE ACB opened at $6.84 on Thursday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.98 and a current ratio of 2.37. The company has a market cap of $6.94 billion, a P/E ratio of 68.40 and a beta of 2.50. The company has a fifty day moving average of $7.47. Aurora Cannabis has a 52-week low of $4.05 and a 52-week high of $12.52.

Aurora Cannabis (NYSE:ACB) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.05). The company had revenue of $49.00 million during the quarter, compared to the consensus estimate of $50.92 million. Aurora Cannabis had a negative net margin of 122.65% and a positive return on equity of 1.24%. As a group, equities analysts anticipate that Aurora Cannabis will post -0.23 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the company. Deutsche Bank AG bought a new stake in shares of Aurora Cannabis in the 4th quarter worth about $3,105,000. D. E. Shaw & Co. Inc. purchased a new position in shares of Aurora Cannabis during the 4th quarter worth about $10,504,000. Swiss National Bank boosted its stake in shares of Aurora Cannabis by 5.9% during the 1st quarter. Swiss National Bank now owns 2,443,965 shares of the company’s stock worth $22,117,000 after purchasing an additional 136,300 shares during the period. Private Advisor Group LLC boosted its stake in shares of Aurora Cannabis by 33.1% during the 1st quarter. Private Advisor Group LLC now owns 147,763 shares of the company’s stock worth $1,339,000 after purchasing an additional 36,765 shares during the period. Finally, CNB Bank boosted its stake in shares of Aurora Cannabis by 100.0% during the 1st quarter. CNB Bank now owns 4,000 shares of the company’s stock worth $36,000 after purchasing an additional 2,000 shares during the period. Hedge funds and other institutional investors own 9.00% of the company’s stock.

About Aurora Cannabis

Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.

Featured Article: What are the most popular ETFs

Analyst Recommendations for Aurora Cannabis (NYSE:ACB)

Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.